To investigate whether the mechanism underlying the anti-tumour effect of Mettl1 deletion was due to tumour cell intrinsic pathways or to the tumour immune microenvironment, we injected tumour cells isolated from Pten-KO/Mettl1 + / + and Pten-KO/Mettl1fl/fl mouse prostates into NOD scid gamma (NSG) immune-incompetent mice. The gene discussed is METTL1; the disease is neoplasm.